1.32
0.76%
+0.01
Dopo l'orario di chiusura:
1.32
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché THTX Giù?
Forum
Previsione
Frazionamento azionario
Theratechnologies Inc. Borsa (THTX) Ultime notizie
Theratechnologies (TSE:TH) Share Price Passes Below 200-Day Moving Average of $2.03 - MarketBeat
MarketBeat
Closing Bell: Theratechnologies down on Friday (TH) - The Globe and Mail
The Globe and Mail
Theratechnologies Announces New Board Chair - TipRanks.com - TipRanks
TipRanks
Theratechnologies Elects New Board Chair - TipRanks.com - TipRanks
TipRanks
Theratechnologies Reports on its Annual Meeting of Shareholders - GlobeNewswire
GlobeNewswire
Theratechnologies rend compte de son assemblée annuelle des actionnaires
GlobeNewswire Inc.
Increases to CEO Compensation Might Be Put On Hold For Now at Theratechnologies Inc. (TSE:TH) - Simply Wall St
Simply Wall St
Increases to CEO Compensation Might Be Put On Hold For Now at Theratechnologies Inc. (TSE:TH) - Simply Wall St
Simply Wall St
Theratechnologies présentera des données à long terme sur l’efficacité, l’innocuité et la pharmacocinétique de l’utilisation du TH1902 (sudocétaxel zendusortide) dans les tumeurs solides lors du Congrès 2024 de l’ASCO
GlobeNewswire Inc.
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel ... - GlobeNewswire
GlobeNewswire
Theratechnologies (THTX) Upgraded to Buy: What Does It Mean for the Stock?
Zacks Investment Research
SGIOY: 3 Biotech Stocks to Buy to Power Through April - StockNews.com
StockNews.com
Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders
GlobeNewswire Inc.
Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of ... - GlobeNewswire
GlobeNewswire
Theratechnologies First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Simply Wall St
Simply Wall St
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
GlobeNewswire Inc.
Leede still bullish on Theratechnologies following “soft” quarter - Cantech Letter
Cantech Letter
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024
GlobeNewswire Inc.
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024 - Yahoo Finance
Yahoo Finance
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform
GlobeNewswire Inc.
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ ... - GlobeNewswire
GlobeNewswire
Theratechnologies Strengthens Board with New Appointment - TipRanks.com - TipRanks
TipRanks
Theratechnologies Appoints Elina Tea to its Board of Directors
GlobeNewswire Inc.
Theratechnologies Appoints Elina Tea to its Board of Directors - GlobeNewswire
GlobeNewswire
Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update
GlobeNewswire Inc.
Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology ... - Yahoo Finance
Yahoo Finance
Theratechnologies Announces Update on its Preclinical Oncology Research Program
GlobeNewswire Inc.
Theratechnologies phases down preclinical oncology research | 2024-03-22 | Investing News - Stockhouse Publishing
Stockhouse Publishing
Theratechnologies nomme Jordan Zwick à son conseil d’administration
GlobeNewswire Inc.
Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
GlobeNewswire Inc.
Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced ... - GlobeNewswire
GlobeNewswire
CORRECTION - Theratechnologies annonce la démission de l’un de ses administrateurs, M. Alain Trudeau
GlobeNewswire Inc.
Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau
GlobeNewswire Inc.
Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau - GlobeNewswire
GlobeNewswire
Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDA
GlobeNewswire Inc.
Theratechnologies Faces FDA Setback on Trogarzo - TipRanks.com - TipRanks
TipRanks
Theratechnologies (THTX) Shows Fast-paced Momentum But Is Still a Bargain Stock
Zacks Investment Research
BMRN: Eyeing Growth? Check Out These 3 Biotech Stock Buys - StockNews.com
StockNews.com
Earnings Update: Theratechnologies Inc. (TSE:TH) Just Reported And Analysts Are Trimming Their Forecasts - Simply Wall St
Simply Wall St
Theratechnologies présente ses résultats financiers pour le quatrième trimestre et l’exercice complet 2023 et des prévisions pour 2024
GlobeNewswire Inc.
Theratechnologies: Fiscal Q4 Earnings Snapshot - Quartz
Quartz
Theratechnologies annonce la publication d’un article dans Frontiers in Immunology qui approfondit la compréhension du mécanisme d’action moléculaire du sudocétaxel zendusortide (TH1902)
GlobeNewswire Inc.
Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
GlobeNewswire Inc.
Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
GlobeNewswire Inc.
Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update - Yahoo Finance
Yahoo Finance
FDA denies approval for Theratechnologies' tesamorelin F8 - Pharmaceutical Technology
Pharmaceutical Technology
Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA
GlobeNewswire Inc.
Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA - GlobeNewswire
GlobeNewswire
Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License Application
GlobeNewswire Inc.
Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License Application - GlobeNewswire
GlobeNewswire
Capitalizzazione:
|
Volume (24 ore):